Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 3;14(1):55.
doi: 10.1007/s13668-025-00645-0.

Urolithin as a Metabolite of Ellagitannins and Ellagic Acid from Fruits and Nuts Produced by the Gut Microbiota: Its Role on Non-Communicable Diseases

Affiliations
Review

Urolithin as a Metabolite of Ellagitannins and Ellagic Acid from Fruits and Nuts Produced by the Gut Microbiota: Its Role on Non-Communicable Diseases

Marcia Ribeiro et al. Curr Nutr Rep. .

Abstract

Purpose of review: This narrative review investigates how urolithins produced by the gut microbiota can regulate transcription factors (such as NRF2, NF-kB, and PPAR-γ) associated with senescence, inflammation, and imbalanced redox status. It also discusses the potential benefits of urolithins for patients with chronic diseases, including cardiovascular disease, cancer, diabetes, obesity, and chronic kidney disease.

Recent findings: Studies have shown that urolithins have many health benefits, including anti-inflammatory, antioxidant, antimicrobial, and anti-atherosclerotic effects. They are also linked to improved mitochondrial function and imbalanced redox associated with activating the Nrf2/ARE pathway. Urolithins are metabolites produced by gut microbiota from ellagic acid and ellagitannins, polyphenols primarily found in nuts and fruits, including pomegranates and berries like raspberries, cloudberries, and blackberries.

Keywords: Chronic diseases; Ellagic acid; Fruits; Gut microbiota; Urolithin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

Similar articles

Cited by

References

    1. Doenças cardiovasculares (DCV). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases... ). Accessed 7 Jan 2024
    1. Soomro S, Mesaik MA, Shaheen F, et al. Inhibitory Effects of Myrtucommuacetalone 1 (MCA-1) from Myrtus Communis on Inflammatory Response in Mouse Macrophages. Molecules. 2020;25:13. https://doi.org/10.3390/MOLECULES25010013 . - DOI
    1. Potrykus M, Czaja-Stolc S, Stankiewicz M, et al. Intestinal microbiota as a contributor to chronic inflammation and its potential modifications. Nutrients. 2021;13:1–20. https://doi.org/10.3390/nu13113839 . - DOI
    1. Mafra D, Borges NA, Lindholm B, et al. Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nat Rev Nephrol. 2021;17:153–71. https://doi.org/10.1038/S41581-020-00345-8 . - DOI - PubMed
    1. Derosa G, Maffioli P, Sahebkar A. Ellagic Acid and Its Role in Chronic Diseases. Adv Exp Med Biol. 2016;928:473–9. https://doi.org/10.1007/978-3-319-41334-1_20 . - DOI - PubMed

MeSH terms

LinkOut - more resources